preclinical drug Articles
-
How much do animal models play a role in drug development?
Published by Vijay K Singh and Thomas M Seed on September 3, 2021, in Expert Opinion on Drug Discovery and deals with the necessity of animal models for modern drug research in the direction of animal strains, animal models, requirements, and pathways for developing new drugs. The use of experimental animal models in drug development aids in the understanding of disease and/or related conditions' ...
-
Four Well-Established Strategies Used in Hit Identification
The major preclinical phases of peptide drug discovery encompass initial target identification and validation, hit identification, high throughput screening, lead optimization, etc. Among them, hit identification is one of the most critical steps in identifying peptides that can interact with well-validated targets. Hit identification (HI) follows the process of target validation, in which the ...
-
Advancing Cancer Treatments with ALZET Osmotic Pumps
The research summarized in this whitepaper provides a number of examples of how ALZET® pumps offer a superior pre-clinical drug dosing option for the delivery of a wide array of anti-cancer agents, including small molecules, immunotherapies, radiotherapies, combination treatments, and novel drug entities. This whitepaper also explores how ALZET® pumps have been used to successfully test ...
-
A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform
Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate’s volume of distribution are error-prone, time and cost intensive and lack reproducibility in clinical settings. The paper demonstrates how a computational platform integrating ...
By VeriSIM Life
-
What’s a life-saving drug worth? It depends…
The risk? According to Medicinenet.com, only 5 in 5,000 drugs that enter preclinical testing advance to human trials. And only 1 of these 5 drugs ultimately gets approved for sale, which means the chance for a new drug to make it to market is 1 in 5,000. That’s a lot of R&D ...
By Vistex Inc
-
OneThree`s Workflow for Predicting Drug Toxicity - Case study
Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was builtin a lab setting; allowing us to engineer our methodologies around real-world results. While working with major biotech and pharma partners; ...
-
Global ADC Drug Overview
In recent years, antibody-drug conjugates (ADCs) have been widely sought after due to their excellent clinical performance and market returns. ADC drugs are composed of three parts: antibody, effector molecule (Payload, usually cytotoxic agent) and linker. Compared with traditional drugs, ADC drugs have obvious advantages in improving targeting and reducing side effects. 1. Global ADC listing ...
By BOC Sciences
-
Understanding the Importance of Preclinical Animal Models in Drug Development
In the world of pharmaceuticals, developing safe and effective drugs is a complex and time-consuming process. Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. One critical component of this evaluation is the use of preclinical animal models. Preclinical ...
-
Pooled Human Cryopreserved Hepatocytes
Hepatocytes are the chief functional cells of the liver, responsible for the selective uptake, metabolism and excretion of most drugs. Cells for use in plate cultures or suspension assays represent a key tool for predicting properties such as hepatotoxicity, metabolism, and potential drug-drug interactions. Since these cells mimic the properties of the liver, researchers can evaluate the ...
-
The Toxicity Atlas - One year later
It’s been about a year since I started my PhD project named The Toxicity Atlas. In this four-year project, I’m collaborating with researchers from Amsterdam UMC and my colleagues at Medstone to find better treatment options for patients with brain cancer. Let me tell you more about my results so far. Information databases Developing new drugs costs a lot of money and a lot of ...
-
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials. Organ-on-a-chip models are the closest ...
-
Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding
Broad-spectrum matrix metalloproteinase (MMP) inhibitors (MMPI) were unsuccessful in cancer clinical trials, partly due to side effects resulting from limited knowledge of the full repertoire of MMP substrates, termed the substrate degradome, and hence the in vivo functions of MMPs. To gain further insight into the degradome of MMP-14 (membrane type 1 MMP) an MMPI, prinomastat (drug code AG3340), ...
-
Organoid Models of SARS-CoV-2 Infection learned from COVID-19
The clinical presentation of COVID-19-related illness ranges from asymptomatic to mild respiratory symptoms resembling influenza infection to acute symptoms including pneumonia requiring hospitalization and admission to the intensive care unit. COVID-19 starts in the upper airways and lungs, but in severe cases can also affect the heart, blood vessels, brain, liver, kidneys, and intestines. ...
-
Enhancing Human Gut Tissue Models through Gene Editing
The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for next-generation preclinical models, but obtaining these tissues is challenging. Gene editing enables Altis Biosystems to offer a diverse array of RepliGut® human gut models tailored for specific research programs. Many Challenges Around Accessing Tissues ...
-
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you